Cancer Research UK funded, 2019 - 2024
Advances in sequencing technology have catalysed dramatic expansion in genetic cancer susceptibility testing and there is an increasing drive to embed genomics into the UK National Health System.
Expansion of genetic testing and increased identification of individuals with inherited genetic cancer susceptibility offers an opportunity for saving lives through early detection and prevention of cancer by effective targeting of resource to those at highest risk.
To ensure safe and effective expansion of genetic testing into clinical care, best outcomes for patients, and equality of care throughout the NHS, tools and resources are required that enable translation of knowledge gained through research into clinical practice.
Funded by Cancer Research UK, the 5-year CanGene-CanVar programme (April 2019 - March 2024) aims to create an interface between NHS and research settings that will underpin future expansions in genetic testing access.
Through six interlinked work-packages we will generate for tomorrow better evidence regarding cancer genetic risk from nationally available data. In concert, through clinical-facing resources, tools, and education we shall ensure the best evidence available today is applied effectively and consistently across our national NHS clinical and laboratory systems.